Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Fulcrum Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Pharmaceutical Preparations
No intraday reading yet this session.
Fulcrum Therapeutics, Inc. has 6 disclosed suppliers and 1 disclosed customer. Each one is named in an SEC filing, either Fulcrum Therapeutics, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In May 2024, we entered into a collaboration and license agreement with Sanofi, pursuant to which we granted Sanofi an exclusive license under certain intellectual property rights to commercialize losmapimod, an oral small molecule that we were developing for the treatment of FSHD outside of the United States and received an upfront payment of $80.0 million.”
FILING10-K0001193125-26-065197cik 0001680581
“In December 2025, pursuant to an underwriting agreement with J.P. Morgan Securities LLC, Leerink Partners LLC, and Cantor Fitzgerald & Co., we and issued and sold (i) 11,851,853 shares of our common stock at a public offering price of $13.50 per share and (ii) pre-funded warrants to purchase up to 1,111,193 shares of our common stock at a public offering price of $13.499 per pre-funded warrant.”
FILING10-K0001193125-26-065197cik 0001680581
“In exchange for the license rights, Fulcrum paid us a $0.4 million upfront payment.”
FILING10-K0001736730-26-000016cik 0001736730disclosed by CAMP
“• make any milestone payments to CAMP4 under our license agreement with CAMP4;”
FILING10-K0001193125-26-065197cik 0001680581
“In December 2025, pursuant to an underwriting agreement with J.P. Morgan Securities LLC, Leerink Partners LLC, and Cantor Fitzgerald & Co., we and issued and sold (i) 11,851,853 shares of our common stock at a public offering price of $13.50 per share and (ii) pre-funded warrants to purchase up to 1,111,193 shares of our common stock at a public offering price of $13.499 per pre-funded warrant.”
FILING10-K0001193125-26-065197cik 0001680581
“In December 2025, pursuant to an underwriting agreement with J.P. Morgan Securities LLC, Leerink Partners LLC, and Cantor Fitzgerald & Co., we and issued and sold (i) 11,851,853 shares of our common stock at a public offering price of $13.50 per share and (ii) pre-funded warrants to purchase up to 1,111,193 shares of our common stock at a public offering price of $13.499 per pre-funded warrant.”
FILING10-K0001193125-26-065197cik 0001680581
“In February 2024, we entered into a controlled equity offering sm agreement with Cantor Fitzgerald & Co. and Stifel, Nicolaus & Company, Incorporated, as agents, with respect to an at-the-market offering program pursuant to which we may offer and sell, from time to time in our sole discretion, shares of our common stock, par value $0.001 per share, having an aggregate offering price of up to $100.0 million through the agents.”
FILING10-K0001193125-26-065197cik 0001680581
Watchlist prices, news filtered to it, and its next report on your desk.
FULC (Fulcrum Therapeutics, Inc.) has 6 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: SNY −2.03%, in industrials & materials.